Private Wealth Partners LLC grew its position in CareDx, Inc. (NASDAQ:CDNA) by 2,250.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 235,000 shares of the company’s stock after acquiring an additional 225,000 shares during the quarter. Private Wealth Partners LLC owned 0.91% of CareDx worth $869,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the business. Thompson Davis & CO. Inc. increased its position in shares of CareDx by 3,294.9% during the 3rd quarter. Thompson Davis & CO. Inc. now owns 203,692 shares of the company’s stock valued at $754,000 after purchasing an additional 197,692 shares during the last quarter. Gagnon Securities LLC boosted its holdings in CareDx by 2.9% during the 2nd quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock valued at $2,314,000 after acquiring an additional 57,954 shares during the period. Perkins Capital Management Inc. purchased a new position in CareDx during the 3rd quarter valued at $513,000. Royce & Associates LP boosted its holdings in CareDx by 39.3% during the 2nd quarter. Royce & Associates LP now owns 733,287 shares of the company’s stock valued at $814,000 after acquiring an additional 206,815 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in CareDx during the 2nd quarter valued at $212,000. 25.06% of the stock is currently owned by institutional investors and hedge funds.
Shares of CareDx, Inc. (CDNA) traded up $0.31 during mid-day trading on Wednesday, hitting $6.50. The stock had a trading volume of 510,700 shares, compared to its average volume of 351,587. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53. CareDx, Inc. has a fifty-two week low of $0.76 and a fifty-two week high of $6.69.
CareDx (NASDAQ:CDNA) last posted its earnings results on Thursday, November 9th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.02. The firm had revenue of $12.19 million for the quarter, compared to analyst estimates of $12.05 million. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. research analysts anticipate that CareDx, Inc. will post -0.83 EPS for the current year.
In other CareDx news, major shareholder Neil Gagnon purchased 10,642 shares of the stock in a transaction on Thursday, October 5th. The shares were bought at an average price of $4.00 per share, for a total transaction of $42,568.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have purchased 73,705 shares of company stock worth $224,339. 5.40% of the stock is owned by corporate insiders.
Several equities research analysts have weighed in on CDNA shares. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Craig Hallum restated a “buy” rating and set a $10.00 price objective (up from $4.00) on shares of CareDx in a research note on Monday, October 9th. Raymond James Financial, Inc. upgraded CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Wednesday, September 27th. ValuEngine upgraded CareDx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $7.00 target price (up from $3.00) on shares of CareDx in a research report on Tuesday, September 26th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $6.69.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.